title: Immunomodulatory effects of low dose cis-Diaminedichloroplatinum (cisplatin) combined with UFT and PSK in patients with advanced colorectal cancer.
abstract: It is well known that cell-mediated immunity is suppressed in patients with neoplastic diseases. We have reported that soluble receptors for interleukin-2 (sIL-2R) and tumor necrosis factor (sTNF-R1) are elevated in the serum of patients with advanced colorectal cancer. The presence of these soluble receptors and immunosuppressive cytokines, including interleukin-10 (IL-10), might be important in the mechanisms of immunosuppression. cis-Diaminedichloroplatinum (cisplatin) has been reported to immunomodulate, especially when used in low dose in combination with 5-Fluorouracil (5-FU). In this study, cisplatin and UFT, a form of uracil and tegafur which is a prodrug of 5-FU, were administered with immunomodulator Polysaccharide K (PSK) to ten patients with colorectal cancer, who showed distant metastasis in the liver or lung, and the serum levels of sIL-2R and sTNF-R1 and the production of gamma-interferon (gamma-INF) and interleukin-10 by peripheral blood mononuclear cells were measured. The serum concentrations of sIL-2R and the production of IL-10 were reduced (p < 0.05) after 2 months of treatment. Thus, this combination appeared to have immunomodulative potential in patients with advanced colorectal cancer.
authors.affiliation: First Department of Surgery, Nihon University School of Medicine, 30-1 Oyaguchi-kamimachi, Tokyo 173-0032, Japan.
authors.forename: Masahiko
authors.initials: M
authors.lastname: Shibata
authors.forename: Takeshi
authors.initials: T
authors.lastname: Nezu
authors.forename: Hisao
authors.initials: H
authors.lastname: Kanou
authors.forename: Yasuhiko
authors.initials: Y
authors.lastname: Nagata
authors.forename: Tomo
authors.initials: T
authors.lastname: Kimura
authors.forename: Motoo
authors.initials: M
authors.lastname: Takekawa
authors.forename: Katsuyuki
authors.initials: K
authors.lastname: Ando
authors.forename: Masahiro
authors.initials: M
authors.lastname: Fukuzawa
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage*; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000601:surgery; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007167:Immunotherapy; D016753:Interleukin-10 / Q000097:blood; D008297:Male; D008875:Middle Aged; D011135:Polysaccharides, Bacterial / Q000627:therapeutic use*; D012004:Rectal Neoplasms / Q000188:drug therapy* / Q000601:surgery; D005641:Tegafur / Q000008:administration & dosage*; D014498:Uracil / Q000008:administration & dosage*
chemical_list: D011135:Polysaccharides, Bacterial; D016753:Interleukin-10; D005641:Tegafur; D014498:Uracil; D002945:Cisplatin